Home Compounds Longevity & Mitochondrial CoQ10 (Ubiquinol)
Longevity & Mitochondrial Research Moderate Evidence

CoQ10 (Ubiquinol)

Mitochondrial electron transport chain cofactor. Studied for cardiovascular disease, statin-associated myopathy, heart failure, and mitochondrial dysfunction. Levels decline with age and statin use.

mitochondriaCoQ10ubiquinolcardiovascularheart failureantioxidantstatin
Half-life
33 hours; once-daily dosing with fat-containing meal
SKUs
2
Evidence
Moderate Evidence

Coenzyme Q10 (CoQ10) is a compound that the body produces naturally and that plays a central role in the mitochondrial energy production chain. It also functions as an antioxidant. CoQ10 levels decline with age and with use of certain medications, particularly statins. It has been studied for cardiovascular health, heart failure, mitochondrial disease, and as a general supplement for energy and antioxidant support.

Heart Failure Research
The Q-SYMBIO trial — one of the larger CoQ10 trials — studied 420 patients with moderate-to-severe heart failure. The CoQ10 group had significantly lower rates of major adverse cardiovascular events and cardiovascular mortality compared to placebo at two years. This was a meaningful finding in a difficult-to-treat condition.
Statin-Associated Muscle Symptoms
Statins reduce the body's production of CoQ10 alongside cholesterol. Supplementation has been studied as a way to reduce statin-associated muscle pain and fatigue. Results from trials are mixed — some show benefit, others show no significant effect compared to placebo.
Mitochondrial Disease
For people with certain mitochondrial disorders, CoQ10 supplementation is often part of standard supportive management. Research in these populations shows improvements in energy levels and mitochondrial function markers, though CoQ10 is not a cure for these conditions.
Blood Pressure Research
Meta-analyses of small trials have suggested CoQ10 supplementation may modestly reduce systolic blood pressure. Effect sizes are modest but consistent across studies, and the safety profile makes it a low-risk addition to research protocols.
  • Q-SYMBIO trial showed reduction in major cardiovascular events and cardiovascular mortality in heart failure patients.
  • Meta-analyses suggest modest reductions in blood pressure with supplementation.
  • Mixed evidence for reducing statin-associated muscle symptoms.
  • Supportive evidence for use in mitochondrial disorders.
  • Well-tolerated with a long safety record across many studies.

The Q-SYMBIO trial findings have not been replicated in a similarly large trial, which means the heart failure findings, while interesting, need confirmation. For most other applications, the evidence is from small trials and meta-analyses of heterogeneous studies. Oral bioavailability of CoQ10 is relatively low and varies significantly between formulations. Ubiquinol forms may have higher bioavailability than ubiquinone forms.

Every cell in your body uses a chain of reactions inside mitochondria to convert food into usable energy. CoQ10 is an essential part of that chain — it acts as a shuttle, carrying electrons between the protein complexes that drive energy production. Without enough CoQ10, this process becomes less efficient. CoQ10 also acts as an antioxidant, capturing harmful reactive oxygen species produced as a byproduct of energy metabolism before they can damage cell structures. As you age, your body naturally produces less CoQ10. Statins, which block a pathway shared with CoQ10 synthesis, can accelerate this decline. Supplementing CoQ10 aims to restore levels that may have dropped below the amount needed for optimal mitochondrial function.

CoQ10 has an excellent safety record across decades of research and supplementation use. Side effects are uncommon and mild — occasional GI symptoms. It is a common over-the-counter supplement. It may have mild blood pressure lowering effects, which is worth noting for people already on blood pressure medications. It can potentially interact with warfarin at high doses. It is not FDA-approved as a drug but is widely available as a supplement.

Moderate Evidence

This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.

Published Research Ranges
100–400mg/day typical research range; higher doses (600–1200mg/day) in specific conditions
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.

Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.

Coenzyme Q10 in Heart Failure Mortality and Morbidity (Q-SYMBIO): RCT
JACC: Heart Failure • 2014  • DOI: 10.1016/j.jchf.2014.06.008
View Source
CoQ10 and Statin-Associated Muscle Symptoms: Systematic Review
Pharmacological Research • 2015  • DOI: 10.1016/j.phrs.2015.01.024
View Source
Coenzyme Q10 in Aging, Oxidative Stress, and Metabolic Syndrome
Antioxidants & Redox Signaling • 2011  • DOI: 10.1089/ars.2009.2944
View Source
Survival in critical illness is associated with early activation of mitochondrial biogenesis
 • 2010  • DOI: 10.1164/rccm.201003-0326oc
View Source
The molecular and metabolic landscape of iron and ferroptosis in cardiovascular disease
 • 2023  • DOI: 10.1038/s41569-022-00735-4
View Source
GPX4 in cell death, autophagy, and disease
 • 2023  • DOI: 10.1080/15548627.2023.2218764
View Source
The interaction between ferroptosis and inflammatory signaling pathways
 • 2023  • DOI: 10.1038/s41419-023-05716-0
View Source
The diversified role of mitochondria in ferroptosis in cancer
 • 2023  • DOI: 10.1038/s41419-023-06045-y
View Source
The Role of Oxidative Stress in Atherosclerosis
 • 2022  • DOI: 10.3390/cells11233843
View Source
p53 in ferroptosis regulation: the new weapon for the old guardian
 • 2022  • DOI: 10.1038/s41418-022-00943-y
View Source
Ferroptosis: mechanisms, biology and role in disease
 • 2021  • DOI: 10.1038/s41580-020-00324-8
View Source
Ferroptosis: a cell death connecting oxidative stress, inflammation and cardiovascular diseases
 • 2021  • DOI: 10.1038/s41420-021-00579-w
View Source
Fibromyalgia: Pathogenesis, Mechanisms, Diagnosis and Treatment Options Update
 • 2021  • DOI: 10.3390/ijms22083891
View Source
NLRP3 inflammasome activation and cell death
 • 2021  • DOI: 10.1038/s41423-021-00740-6
View Source
The diverse functionality of NQO1 and its roles in redox control
 • 2021  • DOI: 10.1016/j.redox.2021.101950
View Source
The interaction between ferroptosis and lipid metabolism in cancer
 • 2020  • DOI: 10.1038/s41392-020-00216-5
View Source
Oxidative Damage and Antioxidant Defense in Ferroptosis
 • 2020  • DOI: 10.3389/fcell.2020.586578
View Source
Breakdown of an Ironclad Defense System: The Critical Role of NRF2 in Mediating Ferroptosis
 • 2020  • DOI: 10.1016/j.chembiol.2020.03.011
View Source
Oxidative stress and male infertility: current knowledge of pathophysiology and role of antioxidant therapy in disease management
 • 2020  • DOI: 10.1007/s00018-019-03253-8
View Source
Cellular adaptation to hypoxia through hypoxia inducible factors and beyond
 • 2020  • DOI: 10.1038/s41580-020-0227-y
View Source
PGC-1α, Inflammation, and Oxidative Stress: An Integrative View in Metabolism
 • 2020  • DOI: 10.1155/2020/1452696
View Source
ROS and diseases: role in metabolism and energy supply
 • 2020  • DOI: 10.1007/s11010-019-03667-9
View Source
Ferroptosis: past, present and future
 • 2020  • DOI: 10.1038/s41419-020-2298-2
View Source
An Overview of Nrf2 Signaling Pathway and Its Role in Inflammation
 • 2020  • DOI: 10.3390/molecules25225474
View Source
Iron Metabolism in Ferroptosis
 • 2020  • DOI: 10.3389/fcell.2020.590226
View Source
Reactive Oxygen Species: Drivers of Physiological and Pathological Processes
 • 2020  • DOI: 10.2147/jir.s275595
View Source
Reactive Oxygen Species-Induced Lipid Peroxidation in Apoptosis, Autophagy, and Ferroptosis
 • 2019  • DOI: 10.1155/2019/5080843
View Source
The development of the concept of ferroptosis
 • 2019  • DOI: 10.1016/j.freeradbiomed.2018.09.043
View Source
Mitochondrial dysfunction and oxidative stress in heart disease
 • 2019  • DOI: 10.1038/s12276-019-0355-7
View Source
Sources of Vascular Nitric Oxide and Reactive Oxygen Species and Their Regulation
 • 2019  • DOI: 10.1152/physrev.00036.2017
View Source
A randomized trial of coenzyme Q10 in patients with confirmed statin myopathy
 • 2015  • DOI: 10.1016/j.atherosclerosis.2014.12.016
View Source
Coenzyme Q(10) and selenium in statin-associated myopathy treatment
 • 2013  • DOI: 10.1139/cjpp-2012-0118
View Source
Coenzyme Q10 as an adjunctive in the treatment of chronic congestive heart failure. The Q10 Study Group
 • 1995  • DOI: 10.1016/1071-9164(95)90011-x
View Source
Usefulness of taurine in chronic congestive heart failure and its prospective application
 • 1992  • DOI: 10.1253/jcj.56.95
View Source
Response of patients in classes III and IV of cardiomyopathy to therapy in a blind and crossover trial with coenzyme Q10
 • 1985  • DOI: 10.1073/pnas.82.12.4240
View Source
Effects of Coenzyme Q10 on Statin-Induced Myopathy: An Updated Meta-Analysis of Randomized Controlled Trials
 • 2018  • DOI: 10.1161/jaha.118.009835
View Source
Introducing the 'Drucebo' effect in statin therapy: a systematic review of studies comparing reported rates of statin-associated muscle symptoms, under blinded and open-label conditions
 • 2018  • DOI: 10.1002/jcsm.12344
View Source
Effects of coenzyme Q10 on statin-induced myopathy: a meta-analysis of randomized controlled trials
 • 2015  • DOI: 10.1016/j.mayocp.2014.08.021
View Source
Lipid-lowering efficacy of atorvastatin
 • 2015  • DOI: 10.1002/14651858.cd008226.pub3
View Source
Effect of coenzyme Q₁₀ supplementation on heart failure: a meta-analysis
 • 2013  • DOI: 10.3945/ajcn.112.040741
View Source
Corticosteroids for viral myocarditis
 • 2013  • DOI: 10.1002/14651858.cd004471.pub3
View Source
Cardioprotective interventions for cancer patients receiving anthracyclines
 • 2011  • DOI: 10.1002/14651858.cd003917.pub4
View Source
The impact of coenzyme Q10 on systolic function in patients with chronic heart failure
 • 2006  • DOI: 10.1016/j.cardfail.2006.03.007
View Source
Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials
 • 1997  • DOI: 10.1016/s0098-2997(97)00042-3
View Source
Fighting age-related orthopedic diseases: focusing on ferroptosis
 • 2023  • DOI: 10.1038/s41413-023-00247-y
View Source
Glutathione system enhancement for cardiac protection: pharmacological options against oxidative stress and ferroptosis
 • 2023  • DOI: 10.1038/s41419-023-05645-y
View Source
Targeting Iron Metabolism and Ferroptosis as Novel Therapeutic Approaches in Cardiovascular Diseases
 • 2023  • DOI: 10.3390/nu15030591
View Source
Pros and cons for statins use and risk of Parkinson's disease: An updated perspective
 • 2023  • DOI: 10.1002/prp2.1063
View Source
Oxidative Stress and Ischemia/Reperfusion Injury in Kidney Transplantation: Focus on Ferroptosis, Mitophagy and New Antioxidants
 • 2022  • DOI: 10.3390/antiox11040769
View Source
Ferroptosis in heart failure
 • 2022  • DOI: 10.1016/j.yjmcc.2022.10.004
View Source
Therapeutic strategies in ischemic cardiomyopathy: Focus on mitochondrial quality surveillance
 • 2022  • DOI: 10.1016/j.ebiom.2022.104260
View Source
Tubular Mitochondrial Dysfunction, Oxidative Stress, and Progression of Chronic Kidney Disease
 • 2022  • DOI: 10.3390/antiox11071356
View Source
Statins Neuromuscular Adverse Effects
 • 2022  • DOI: 10.3390/ijms23158364
View Source
Long COVID, a comprehensive systematic scoping review
 • 2021  • DOI: 10.1007/s15010-021-01666-x
View Source
Hydrophilic or Lipophilic Statins?
 • 2021  • DOI: 10.3389/fcvm.2021.687585
View Source
Therapeutic potential of targeting oxidative stress in diabetic cardiomyopathy
 • 2021  • DOI: 10.1016/j.freeradbiomed.2021.03.046
View Source
Inflammation in Human Heart Failure: Major Mediators and Therapeutic Targets
 • 2021  • DOI: 10.3389/fphys.2021.746494
View Source
Effects of statins on mitochondrial pathways
 • 2021  • DOI: 10.1002/jcsm.12654
View Source
Statin-Associated Myopathy: Emphasis on Mechanisms and Targeted Therapy
 • 2021  • DOI: 10.3390/ijms222111687
View Source
Role of mitochondria, oxidative stress and the response to antioxidants in myalgic encephalomyelitis/chronic fatigue syndrome: A possible approach to SARS-CoV-2 'long-haulers'?
 • 2021  • DOI: 10.1016/j.cdtm.2020.11.002
View Source

60 sources · Platform research library · Not generated by AI

COQ100COQ200

Want More Detailed Research?

Ask the AI anything about CoQ10 (Ubiquinol) - mechanisms, trial summaries, pharmacokinetics, and comparisons.

Ask AI About CoQ10 (Ubiquinol)
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.